MedPath

Manual vs. Automated moNitoring Accuracy of GlucosE.

Conditions
blood glucose regulationcritically ill patients
Registration Number
NL-OMON21703
Lead Sponsor
Academic Medical CenterMeibergdreef 91105 AZ AmsterdamThe NetherlandsOptiScan Biomedical CorporationHayward (CA)United States of America
Brief Summary

/A

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Not specified
Target Recruitment
75
Inclusion Criteria

1. Signed Informed consent;

2. Age ≥ 18 years;

Exclusion Criteria

1. Have received any investigational product or been treated with an investigational device within the past 30 days;

2. Pregnancy;

Study & Design

Study Type
Observational non invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
13-aug-2012:<br>1. Glucose prediction error, defined as the results of the YSI versus the OptiScanner, using arterial blood;<br /><br>2. Clarke Error Grid analysis showing the percentage of paired data values falling within each zone between the results of the YSI versus the OptiScanner, using arterial blood;<br /><br>3. Linearity between the results of the YSI versus the OptiScanner, using arterial blood.
Secondary Outcome Measures
NameTimeMethod
13-aug-2012:<br>1. Glucose prediction error, defined as the results of the OptiScanner, versus the RAPIDlab, using arterial blood;<br /><br>2. Clarke Error Grid analysis showing the percentage of paired data values falling within each zone between the results of the OptiScanner versus the RAPIDlab, using arterial blood;<br /><br>3. Linearity between the results of the OptiScanner versus the RAPIDlab, using arterial blood.
© Copyright 2025. All Rights Reserved by MedPath